<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99012">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01732458</url>
  </required_header>
  <id_info>
    <org_study_id>0869-219</org_study_id>
    <secondary_id>2011-006006-27</secondary_id>
    <nct_id>NCT01732458</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Aprepitant for the Prevention of Post Operative Nausea and Vomiting in Children (MK-0869-219 AM3)</brief_title>
  <official_title>A Phase IIb, Partially-Blinded, Randomized, Active Comparator- Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Aprepitant in Pediatric Patients for the Prevention of Post Operative Nausea and Vomiting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the appropriate dosing regimen of aprepitant for
      the prevention of post-operative nausea and vomiting in pediatric participants birth to 17
      years.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum (peak) plasma drug concentration (Cmax)</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum observed plasma concentration (Tmax)</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to infinity (AUC[0-∞])</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent total clearance of the drug from plasma after oral administration (CL/F)</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Aprepitant Terminal Phase Half-Life (t1/2)</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Post-Operative Nausea</condition>
  <condition>Post-Operative Vomiting</condition>
  <arm_group>
    <arm_group_label>Aprepitant Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing will be based on age and weight.  The dose given will be the adult equivalent of 125 mg aprepitant.
A single dose of aprepitant (oral [PO]) and placebo matching ondansetron (intravenous [IV]) will be administered prior to induction of anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aprepitant Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing will be based on age and weight.  The dose given will be the adult equivalent of 40 mg aprepitant.
A single dose of aprepitant (PO) and placebo matching ondansetron (IV) will be administered prior to induction of anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aprepitant Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing will be based on age and weight.  The dose given will be the adult equivalent of 10 mg aprepitant.
A single dose of aprepitant (PO) and placebo matching ondansetron (IV) will be administered prior to induction of anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aprepitant Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing will be based on age and weight.  The dose given will be the adult equivalent of 2.5 mg aprepitant.
A single dose of aprepitant (PO) and placebo matching ondansetron (IV) will be administered prior to induction of anesthesia.
This dose will not be tested if submaximal efficacy is detected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ondansetron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 mg for participants &gt;40 kg in weight; 0.1 mg/kg for participants ≤40 kg in weight.  In participants &lt;1 month of age, the dose of ondansetron will be administered per the product label or based on local standard of care.
A single dose of ondansetron (IV) and placebo matching aprepitant (PO).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant</intervention_name>
    <arm_group_label>Aprepitant Dose 1</arm_group_label>
    <arm_group_label>Aprepitant Dose 2</arm_group_label>
    <arm_group_label>Aprepitant Dose 3</arm_group_label>
    <arm_group_label>Aprepitant Dose 4</arm_group_label>
    <other_name>MK-0869</other_name>
    <other_name>EMEND™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match aprepitant</intervention_name>
    <arm_group_label>Ondansetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <arm_group_label>Ondansetron</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match ondansetron</intervention_name>
    <arm_group_label>Aprepitant Dose 1</arm_group_label>
    <arm_group_label>Aprepitant Dose 2</arm_group_label>
    <arm_group_label>Aprepitant Dose 3</arm_group_label>
    <arm_group_label>Aprepitant Dose 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant enrolled at birth should be at least 37 weeks gestation and ≥3 kg of
             weight

          -  Scheduled to receive general anesthesia AND must have at least one of the following
             risk factors for post-operative nausea and vomiting (PONV) in addition to receiving
             general anesthesia:

               1. scheduled to have a surgery with an associated risk of PONV: tonsillectomy,
                  adenoidectomy, strabismus surgery, dental surgery, hydrocelectomy, orchidopexy
                  or herniorraphy; OR

               2. scheduled to have an operative procedure associated with PONV:

        intraoperative opioid use or anticipated opioid administration within the first 24 hours
        following surgery.

        Exclusion Criteria:

          -  Emergency surgery for a life-threatening condition

          -  Scheduled to receive propofol for maintenance of anesthesia (Note: propofol is
             permitted for induction of anesthesia).

          -  Expected to receive opioid antagonists (e.g., naloxone, naltrexone) or

        benzodiazepine antagonists (e.g., flumazenil)

          -  Scheduled to undergo cardiac or neurosurgery

          -  Vomiting caused by any organic etiology (such as gastric outlet

        obstruction or small bowel obstruction)

          -  Vomiting within 24 hours prior to surgery

          -  Nasogastric or oral gastric tube intra- or post-operatively for suctioning

        gastric contents

          -  Active infection (e.g., pneumonia), congestive heart failure,

        bradyarrythmia, any uncontrolled disease (e.g., diabetic ketoacidosis, gastrointestinal
        obstruction) except for malignancy, or a history of any illness which in the opinion of
        the investigator, might confound the results of the study or pose unwarranted risk to the
        participant

          -  Use of any illicit drugs, including marijuana or has current evidence of alcohol
             abuse
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0031)</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0030)</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0032)</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MSD Brasil</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Germano</last_name>
      <phone>55 11 51897942</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Canada</name>
      <address>
        <city>Kirkland</city>
        <state>Quebec</state>
        <zip>H9H 3L1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Medical Information Centre / Centre de l'information medicale de Merck Canada</last_name>
      <phone>514-428-8600 / 1-800-567-2594</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp and Dohme s.r.o.</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Martinkova</last_name>
      <phone>420 233010213</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD CARD</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soraya Cedraro</last_name>
      <phone>507-282-7200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Pharma Hungary Kft.</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Martinkova</last_name>
      <phone>36 1 457 8522</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Italia S.r.l.</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizia Nardini</last_name>
      <phone>39 06 361911</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Marques</last_name>
      <phone>52 55254819608</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme (I.A.) Corp.</name>
      <address>
        <city>Carolina</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Arbelaez</last_name>
      <phone>(787) 474-8200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme IDEA, Inc.</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Koroleva</last_name>
      <phone>7 0959410000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD (Pty) LTD South Africa</name>
      <address>
        <city>Midrand</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khanyi Mzolo</last_name>
      <phone>27 11 655 3140</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp and Dohme de Espana S.A.</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesar Sanz Rodriguez</last_name>
      <phone>34 913210600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Ilaclari Ltd. Sti</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alev Eren</last_name>
      <phone>90 212 336 12 63</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Chile</country>
    <country>Peru</country>
  </removed_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>November 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
